[{"address1": "1201 Orange Street", "address2": "Suite 600", "city": "Wilmington", "state": "DE", "zip": "19801", "country": "United States", "phone": "484 254 6134", "website": "https://www.nrxpharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "NRx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics that is in phase IIb/III clinical trials for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company has a joint Agreement with Nephron Pharmaceuticals, Inc. to develop intravenous ketamine to treat suicidal depression. The company was founded in 2015 and is based in Wilmington, Delaware.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Jonathan C. Javitt M.D., M.P.H.", "age": 66, "title": "Co-Founder, Chief Scientist Officer & Chairman", "yearBorn": 1957, "fiscalYear": 2022, "totalPay": 873696, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen H. Willard Esq.", "age": 62, "title": "Acting Corporate Secretary, CEO & Director", "yearBorn": 1961, "fiscalYear": 2022, "totalPay": 501186, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Riccardo  Panicucci Ph.D.", "age": 61, "title": "Chief Technology Officer", "yearBorn": 1962, "fiscalYear": 2022, "totalPay": 240000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Seth L. Van Voorhees Ph.D.", "age": 62, "title": "Treasurer", "yearBorn": 1961, "fiscalYear": 2022, "totalPay": 399960, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Richard Clavano Narido", "age": 45, "title": "Interim CFO, Principal Financial Officer & Principal Accounting Officer", "yearBorn": 1978, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Suzanne  Messere", "title": "Investor Relations", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Philip T. Lavin Ph.D.", "age": 76, "title": "Chief Methodologist", "yearBorn": 1947, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Dennis K. McBride Ph.D.", "title": "Chief Strategy Officer & Senior Scientist", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew Patrick Duffy", "age": 60, "title": "Chief Business Officer", "yearBorn": 1963, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.663, "open": 0.7, "dayLow": 0.565, "dayHigh": 0.73, "regularMarketPreviousClose": 0.663, "regularMarketOpen": 0.7, "regularMarketDayLow": 0.565, "regularMarketDayHigh": 0.73, "beta": 0.988, "forwardPE": -2.5196295, "volume": 4388344, "regularMarketVolume": 4388344, "averageVolume": 1547271, "averageVolume10days": 3480690, "averageDailyVolume10Day": 3480690, "bid": 0.66, "ask": 0.6698, "bidSize": 800, "askSize": 900, "marketCap": 62366912, "fiftyTwoWeekLow": 0.221, "fiftyTwoWeekHigh": 1.2, "fiftyDayAverage": 0.43674, "twoHundredDayAverage": 0.392675, "currency": "USD", "enterpriseValue": 56366664, "floatShares": 57198896, "sharesOutstanding": 91675600, "sharesShort": 3868244, "sharesShortPriorMonth": 2920794, "sharesShortPreviousMonthDate": 1705017600, "dateShortInterest": 1707955200, "sharesPercentSharesOut": 0.0454, "heldPercentInsiders": 0.3154, "heldPercentInstitutions": 0.04531, "shortRatio": 5.37, "shortPercentOfFloat": 0.0678, "impliedSharesOutstanding": 91675600, "bookValue": -0.075, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -36059000, "trailingEps": -0.5, "forwardEps": -0.27, "enterpriseToEbitda": -1.705, "52WeekChange": -0.07916665, "SandP52WeekChange": 0.27220368, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "NRXP", "underlyingSymbol": "NRXP", "shortName": "NRX Pharmaceuticals, Inc.", "longName": "NRx Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1512397800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "e9e53629-f0c1-3f0f-8011-e7d950c4534d", "messageBoardId": "finmb_319388181", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.6803, "targetHighPrice": 5.5, "targetLowPrice": 2.0, "targetMeanPrice": 3.17, "targetMedianPrice": 2.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 8902000, "totalCashPerShare": 0.107, "ebitda": -33064000, "totalDebt": 10069000, "quickRatio": 0.461, "currentRatio": 0.677, "returnOnAssets": -1.08969, "returnOnEquity": -6.82612, "freeCashflow": -14752250, "operatingCashflow": -26783000, "financialCurrency": "USD", "trailingPegRatio": null}]